Vio Chemicals
Acquisition in 2023
Vio Chemicals is a manufacturer that provides tailored solutions to various sectors, including chemical, pharmaceutical, cosmetics, food, and nutraceutical industries. The company specializes in developing non-pharmaceutical intermediates such as pigments and produces a range of chemical compounds, including amino acid derivatives, chiral intermediates, chiral ligands, fluorinated aromatics, benzene ring derivatives, and pyridine derivatives. In addition to these products, Vio Chemicals focuses on improving chemical processes and creating materials for electronic devices and water treatment technologies, thereby enhancing the functionality and quality of products across different applications.
celares
Acquisition in 2023
Celares is a biotechnology company specializing in the development and manufacturing of bioconjugate drugs and vaccines for pharmaceutical and diagnostic companies. They produce Good Manufacturing Practice (GMP) grade bioconjugates and functionalized polymers used as excipients in drug formulation, offering customized services such as feasibility studies, process development, upscaling, and analytical method validation to meet clients' specific needs.
Cambridge Research Biochemicals
Acquisition in 2023
Cambridge Research Biochemicals is a prominent independent manufacturer specializing in custom-made peptides and antibodies, serving researchers in the pharmaceutical, life science, and academic sectors globally. The company focuses on providing laboratory-scale reagents that support early-phase drug discovery and biomarker programs in clinical studies. It offers a diverse range of peptides, including simple, modified, stable, radio-labeled, and dye-labeled options, produced in varying quantities from milligrams to grams, all achieved with high purity levels. Additionally, Cambridge Research Biochemicals is recognized for its expertise in generating target-specific antibodies, which can be customized with various modifications and labeling, thereby enhancing research and development efforts in combating diseases.
Fitzgerald Industries International
Acquisition in 2023
Fitzgerald Industries International is a manufacturer and supplier of biological reagents based in Acton, Massachusetts. The company specializes in producing primary and secondary antibodies, recombinant and native proteins, ELISA kits, and serum and plasma. Fitzgerald Industries places a strong emphasis on customer service, striving to meet the unique needs of researchers by offering personalized technical support and customized products. The core team consists of scientists who understand the challenges faced in laboratory settings, allowing them to provide empathetic and effective assistance to their clients. Through a commitment to high-quality products and competitive pricing, Fitzgerald Industries aims to support the scientific community in advancing their research efforts.
EUCODIS Bioscience
Acquisition in 2022
EUCODIS Bioscience GmbH is an enzyme engineering company based in Vienna, Austria, with a subsidiary in Germany. Founded in 2007, the company specializes in the manufacture of high-performing enzyme solutions for diverse applications across the biopharmaceutical, fine chemicals, food and feed, and cosmetics industries. Its product portfolio includes lipases, peroxidases, phospholipase D, nitril hydratases, and various other enzymes, such as catalases and dehydrogenases. These enzymes facilitate processes including the stereospecific resolution of chiral alcohols for API synthesis, the production of sensitive esters, and the synthesis of cosmetic emollient esters. EUCODIS Bioscience also provides services in protein and enzyme engineering, bioprocess development, formulation and analysis, and industrial manufacturing, catering to a growing demand for environmentally sustainable production methods.
Pepscan
Acquisition in 2022
Pepscan is a biotechnology firm specializing in peptide development and production, leveraging 25 years of expertise in the field. Based in Lelystad, the Netherlands, Pepscan provides an extensive range of services, including peptide synthesis, modifications, high-throughput screening, and the production of R&D- to GMP-grade peptides. The company utilizes patented technologies such as CLIPS, which stabilizes peptides in active conformations, and offers phage display capabilities alongside an epitope mapping service platform. These resources enable biotech companies to develop personalized anti-cancer vaccines targeting tumor-specific antigens. Pepscan's comprehensive approach supports clients throughout the entire peptide lifecycle, from research and development to clinical applications, including libraries and neoantigen vaccines.
Aalto Bio Reagents
Acquisition in 2022
Aalto Bio Reagents specializes in developing and supplying biological raw materials and molecular controls for the in-vitro diagnostic and vaccine development industries. The company offers a wide array of products including purified human proteins, monoclonal and polyclonal antibodies, fungal, parasite, bacterial, and viral antigens, as well as disease-state human plasma and biospecimens. These products are crucial for diagnosing and treating emerging diseases such as Chikungunya, Dengue, Zika, and COVID-19. Aalto Bio Reagents serves multinational companies globally, providing essential tools for research and diagnostic applications.
Vivitide
Acquisition in 2022
Vivitide is a biotechnology company that specializes in the production and customization of antibodies and peptides for various industries. They offer peptide arrays, catalog peptides, novel amino acids, derivatives, small molecule synthesis, and resins tailored to meet clients' needs in drug, vaccine, and diagnostic development. Their products are designed to address diverse health challenges such as cancer, diabetes, obesity, infections, and HIV.